Supplementary Figure 10 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of <i>ATM</i> Mutations in Non–Small Cell Lung Cancer
<p>Supplementary Figure 10. (A) Progression-free and (B) overall survival among all patients with stage III NSCLC according to ATM mutation status. (C) Progression-free and (D) overall survival among patients with stage III NSCLC who received concurrent chemoradiotherapy followed by durvalumab...
שמור ב:
| מחבר ראשי: | |
|---|---|
| מחברים אחרים: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| יצא לאור: |
2025
|
| נושאים: | |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
| סיכום: | <p>Supplementary Figure 10. (A) Progression-free and (B) overall survival among all patients with stage III NSCLC according to ATM mutation status. (C) Progression-free and (D) overall survival among patients with stage III NSCLC who received concurrent chemoradiotherapy followed by durvalumab maintenance according to ATM mutation status.</p> |
|---|